Avacopan

Drug Profile

Avacopan

Alternative Names: CCX 168

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; Mario Negri Institute for Pharmacological Research
  • Class Anti-inflammatories; Cyclopentanes; Piperidines; Small molecules
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anti-neutrophil cytoplasmic antibody-associated vasculitis; Haemolytic uraemic syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Phase II Haemolytic uraemic syndrome; IgA nephropathy
  • Phase I Autoimmune disorders

Most Recent Events

  • 14 Feb 2017 Vifor Pharma and ChemoCentryx expand license agreement for rare renal diseases
  • 27 Jan 2017 Chemical structure information added
  • 19 Jan 2017 Vifor Fresenius Medical Care Renal Pharma elects to exercise its option to acquire avcopan from Vifor Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top